SETD2 and chronic myelogenous leukemia, BCR-ABL1 positive: To further investigate the role of SETD2 in the process of imatinib resistance acquisition by CML cells, we next used SETD2‐targeted shRNA to knock down the gene in TF1‐BA cells.